ISR - IsoRay rallies on FDA clearance for use of C4 Imaging's MRI markers

C4 Imaging is pleased to announce that Isoray Medical (ISR) has received U.S. FDA clearance for the use of C4 Imaging’s Sirius positive-signal MRI markers with Isoray’s Cesium-131, brachytherapy seeds.Isoray is the world’s only producer of Cesium-131, commercially known as Cesium Blu™, brachytherapy seeds.The combination will benefit the innovative technology and proprietary isotope to achieve new strides in the ongoing fight against prostate cancer.“Sirius MRI Markers will enable Isoray’s customers to fully utilize the benefits of MRI seed localization.” said Andrew Bright, President and CEO of C4 Imaging.ISR +69.81% AH to $0.90.

For further details see:

IsoRay rallies on FDA clearance for use of C4 Imaging's MRI markers